Ticagrelor-Induced Diarrhea
- PMID: 32134753
- DOI: 10.1097/MJT.0000000000001155
Ticagrelor-Induced Diarrhea
Conflict of interest statement
The authors have no conflicts of interest to declare.
References
-
- Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30:239–245.
-
- Zanchin T, Temperli F, Karagiannis A, et al. Frequency, reasons, and impact of premature ticagrelor discontinuation in patients undergoing coronary revascularization in routine clinical practice: results from the Bern Percutaneous Coronary Intervention Registry. Circ Cardiovasc Interv. 2018;11:e006132.
-
- Serebruany VL, Dinicolantonio JJ, Can MM, et al. Gastrointestinal adverse events after dual antiplatelet therapy: clopidogrel is safer than ticagrelor, but prasugrel data are lacking or inconclusive. Cardiology. 2013;126:35–40.
-
- Schulze A, Hartung P, Schaefer M, et al. Transient receptor potential ankyrin 1 (TRPA1) channel activation by the thienopyridine-type drugs ticlopidine, clopidogrel, and prasugrel. Cell Calcium. 2014;55:200–207.
-
- Linan-Rico A, Ochoa-Cortes F, Beyder A, et al. Mechanosensory signaling in enterochromaffin cells and 5-HT release: potential implications for gut inflammation. Front Neurosci. 2016;10:564.
LinkOut - more resources
Full Text Sources